147 related articles for article (PubMed ID: 26110767)
1. EGF-Induced Acetylation of Heterogeneous Nuclear Ribonucleoproteins Is Dependent on KRAS Mutational Status in Colorectal Cancer Cells.
Roda D; Castillo J; Telechea-Fernández M; Gil A; López-Rodas G; Franco L; González-Rodríguez P; Roselló S; Pérez-Fidalgo JA; García-Trevijano ER; Cervantes A; Zaragozá R
PLoS One; 2015; 10(6):e0130543. PubMed ID: 26110767
[TBL] [Abstract][Full Text] [Related]
2. Cetuximab-mediated ADCC activity is correlated with the cell surface expression level of EGFR but not with the KRAS/BRAF mutational status in colorectal cancer.
Seo Y; Ishii Y; Ochiai H; Fukuda K; Akimoto S; Hayashida T; Okabayashi K; Tsuruta M; Hasegawa H; Kitagawa Y
Oncol Rep; 2014 May; 31(5):2115-22. PubMed ID: 24626880
[TBL] [Abstract][Full Text] [Related]
3. Baseline MAPK signaling activity confers intrinsic radioresistance to KRAS-mutant colorectal carcinoma cells by rapid upregulation of heterogeneous nuclear ribonucleoprotein K (hnRNP K).
Eder S; Arndt A; Lamkowski A; Daskalaki W; Rump A; Priller M; Genze F; Wardelmann E; Port M; Steinestel K
Cancer Lett; 2017 Jan; 385():160-167. PubMed ID: 27793696
[TBL] [Abstract][Full Text] [Related]
4. Lauric acid can improve the sensitization of Cetuximab in KRAS/BRAF mutated colorectal cancer cells by retrievable microRNA-378 expression.
Weng WH; Leung WH; Pang YJ; Hsu HH
Oncol Rep; 2016 Jan; 35(1):107-16. PubMed ID: 26496897
[TBL] [Abstract][Full Text] [Related]
5. PDEδ inhibition impedes the proliferation and survival of human colorectal cancer cell lines harboring oncogenic KRas.
Klein CH; Truxius DC; Vogel HA; Harizanova J; Murarka S; Martín-Gago P; Bastiaens PIH
Int J Cancer; 2019 Feb; 144(4):767-776. PubMed ID: 30194764
[TBL] [Abstract][Full Text] [Related]
6. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
[TBL] [Abstract][Full Text] [Related]
7. Multiple pathways regulate Cten in colorectal cancer without a Tensin switch.
Thorpe H; Akhlaq M; Jackson D; Al Ghamdi S; Storr S; Martin S; Ilyas M
Int J Exp Pathol; 2015 Dec; 96(6):362-9. PubMed ID: 26852686
[TBL] [Abstract][Full Text] [Related]
8. An unconventional KITENIN/ErbB4-mediated downstream signal of EGF upregulates c-Jun and the invasiveness of colorectal cancer cells.
Bae JA; Yoon S; Park SY; Lee JH; Hwang JE; Kim H; Seo YW; Cha YJ; Hong SP; Kim H; Chung IJ; Kim KK
Clin Cancer Res; 2014 Aug; 20(15):4115-28. PubMed ID: 24893630
[TBL] [Abstract][Full Text] [Related]
9. ARID1A facilitates KRAS signaling-regulated enhancer activity in an AP1-dependent manner in colorectal cancer cells.
Sen M; Wang X; Hamdan FH; Rapp J; Eggert J; Kosinsky RL; Wegwitz F; Kutschat AP; Younesi FS; Gaedcke J; Grade M; Hessmann E; Papantonis A; Strӧbel P; Johnsen SA
Clin Epigenetics; 2019 Jun; 11(1):92. PubMed ID: 31217031
[TBL] [Abstract][Full Text] [Related]
10. Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients.
Montagut C; Iglesias M; Arumi M; Bellosillo B; Gallen M; Martinez-Fernandez A; Martinez-Aviles L; Cañadas I; Dalmases A; Moragon E; Lema L; Serrano S; Rovira A; Rojo F; Bellmunt J; Albanell J
Br J Cancer; 2010 Mar; 102(7):1137-44. PubMed ID: 20234366
[TBL] [Abstract][Full Text] [Related]
11. Low frequency KRAS mutations in colorectal cancer patients and the presence of multiple mutations in oncogenic drivers in non-small cell lung cancer patients.
Jiang L; Huang J; Morehouse C; Zhu W; Korolevich S; Sui D; Ge X; Lehmann K; Liu Z; Kiefer C; Czapiga M; Su X; Brohawn P; Gu Y; Higgs BW; Yao Y
Cancer Genet; 2013; 206(9-10):330-9. PubMed ID: 24200637
[TBL] [Abstract][Full Text] [Related]
12. BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis.
Nam SK; Yun S; Koh J; Kwak Y; Seo AN; Park KU; Kim DW; Kang SB; Kim WH; Lee HS
PLoS One; 2016; 11(3):e0151865. PubMed ID: 26991109
[TBL] [Abstract][Full Text] [Related]
13. Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR.
Heinemann V; Stintzing S; Kirchner T; Boeck S; Jung A
Cancer Treat Rev; 2009 May; 35(3):262-71. PubMed ID: 19117687
[TBL] [Abstract][Full Text] [Related]
14. A set of defined oncogenic mutation alleles seems to better predict the response to cetuximab in CRC patient-derived xenograft than KRAS 12/13 mutations.
Chen D; Huang X; Cai J; Guo S; Qian W; Wery JP; Li QX
Oncotarget; 2015 Dec; 6(38):40815-21. PubMed ID: 26512781
[TBL] [Abstract][Full Text] [Related]
15. Association of MicroRNA-31-5p with Clinical Efficacy of Anti-EGFR Therapy in Patients with Metastatic Colorectal Cancer.
Igarashi H; Kurihara H; Mitsuhashi K; Ito M; Okuda H; Kanno S; Naito T; Yoshii S; Takahashi H; Kusumi T; Hasegawa T; Sukawa Y; Adachi Y; Okita K; Hirata K; Imamura Y; Baba Y; Imai K; Suzuki H; Yamamoto H; Nosho K; Shinomura Y
Ann Surg Oncol; 2015 Aug; 22(8):2640-8. PubMed ID: 25472647
[TBL] [Abstract][Full Text] [Related]
16. Differential gene expression signatures between colorectal cancers with and without KRAS mutations: crosstalk between the KRAS pathway and other signalling pathways.
Watanabe T; Kobunai T; Yamamoto Y; Matsuda K; Ishihara S; Nozawa K; Iinuma H; Ikeuchi H; Eshima K
Eur J Cancer; 2011 Sep; 47(13):1946-54. PubMed ID: 21531130
[TBL] [Abstract][Full Text] [Related]
17. Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer.
Seth R; Crook S; Ibrahem S; Fadhil W; Jackson D; Ilyas M
Gut; 2009 Sep; 58(9):1234-41. PubMed ID: 19474002
[TBL] [Abstract][Full Text] [Related]
18. KRAS mutant allele-specific imbalance (MASI) assessment in routine samples of patients with metastatic colorectal cancer.
Malapelle U; Sgariglia R; De Stefano A; Bellevicine C; Vigliar E; de Biase D; Sepe R; Pallante P; Carlomagno C; Tallini G; Troncone G
J Clin Pathol; 2015 Apr; 68(4):265-9. PubMed ID: 25609577
[TBL] [Abstract][Full Text] [Related]
19. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL
Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633
[TBL] [Abstract][Full Text] [Related]
20. Regulation of intestinal myofibroblasts by KRas-mutated colorectal cancer cells through heparin-binding epidermal growth factor-like growth factor.
Kawasaki H; Saotome T; Usui T; Ohama T; Sato K
Oncol Rep; 2017 May; 37(5):3128-3136. PubMed ID: 28339087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]